Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 172 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| Dose exploration | EXPERIMENTAL | Pre-specified nominal doses are proposed in the dose exploration at two dosing frequencies: every two weeks and every three weeks. Intermediate doses may also be used if required based on the Continuous Reassessment Method (CRM) design. |
| Dose expansion | EXPERIMENTAL | Dose and dosing frequency selected from Part 1 dose exploration. |
| Name | Type | Description |
|---|---|---|
| AMG 172 | DRUG | AMG 172 is an antibody drug conjugate |
Inclusion Criteria: * Subjects must have a pathologically documented, definitively diagnosed, clear cell RCC that is relapsed/refractory following at least two lines of systemic therapy (one of which must be a tyrosine kinase), or the subject refuses standard therapy * Measurable disease per RECIST...
AMG 172 is an investigational small molecule being developed for the treatment of renal cell adenocarcinoma, which includes clear cell renal carcinoma and clear cell renal cell carcinoma. It is being studied in patients with kidney cancer.
AMG 172 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The company sponsored the first-in-human study of this investigational drug.
AMG 172 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 first-in-human study in patients with kidney cancer has been completed.
AMG 172 has been studied in one clinical trial, NCT01497821, titled "AMG 172 First in Human Study in Patients With Kidney Cancer." This Phase 1 study enrolled 37 participants and was conducted in the United States, France, and Germany. The trial has been completed.
AMG 172 is a small molecule therapeutic. Its specific molecular target has not been disclosed in available information, so its mechanism of action is not detailed here.